## Edgar Filing: Zausner Meryl - Form 4

Zausner Meryl Form 4											
September 04, 20											
FORM 4	UNITED	STATES					COMMISSIO		PPROVAL 3235-0287		
Washington, D.C. 20549Washington, D.C. 20549Check this box if no longer subject to Section 16.STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP SECURITIESForm 4 or Form 5 obligations 								Expires: Estimated burden hou response	Expires:January 31, 2005Estimated average burden hours per response0.5		
(Print or Type Respo	nses)										
1. Name and Address of Reporting Person <u>*</u> Zausner Meryl			2. Issuer Name <b>and</b> Ticker or Trading Symbol Seres Therapeutics, Inc. [MCRB]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET			3. Date of Earliest Transaction (Month/Day/Year) 08/30/2018			X_ Director 10% Owner Officer (give title Other (specify below) below)					
(Street) CAMBRIDGE, MA 02139			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting					
		( <b>7</b> : )					Person				
(City) (	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	ansaction Date hth/Day/Year)	2A. Deeme Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securiti onAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Report on	a separate line	for each cl	ass of sec	urities bene	ficially own	ned directly	or indirectly.				
					Perso inform requir	ns who res nation cont ed to resp ys a curre	spond to the colle lained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

(Instr. 3)	Price of Derivative Security	(Month/Day/Y	Year) (Instr. 8	<ul> <li>Acquired or Dispose (D) (Instr. 3, 4 and 5)</li> </ul>	ed of				(
			Code	V (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 8.47	08/30/2018	А	30,000		<u>(1)</u>	08/29/2028	Common Stock	30,000

## **Reporting Owners**

Reporting Owner Name / Address		Relationsh		
	Director	10% Owner	Officer	Other
Zausner Meryl C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE, MA 02139	Х			
Signatures				
/s/ Thomas J. DesRosier, Attorney-in-Fact		09/04/2018		
<u>**</u> Signature of Reporting Person		Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option will vest in four equal installments on each anniversary of 08/30/2018 or in full immediately prior to the occurrence of a change in control.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(